Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Biochim Biophys Acta ; 1822(8): 1223-9, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22546842

RESUMO

As recently demonstrated in patients with factor IX deficiency, adeno-associated virus (AAV)-mediated liver-directed therapy is a viable option for inherited metabolic liver disorders. Our aim is to treat Crigler-Najjar syndrome type I (CN I), an inherited severe unconjugated hyperbilirubinemia, as a rare recessive inherited disorder. Because the number of patients eligible for this approach is small, the efficacy can only be demonstrated by a beneficial effect on the pathophysiology in individual patients. Serum bilirubin levels in potential candidates have been monitored since birth, providing an indication of their pathophysiology. Adjuvant phototherapy to prevent brain damage reduces serum unconjugated bilirubin (UCB) levels in CN I patients to the level seen in the milder form of the disease, CN type II. This therapy increases the excretion of UCB, thereby complicating the use of UCB and conjugated bilirubin levels in serum as biomarkers for the gene therapy we try to develop. Therefore, a suitable biomarker that is not affected by phototherapy is currently needed. To this end, we have investigated whether estradiol, ethinylestradiol or ezetimibe could be used as markers for uridine 5'-di-phospho-glucuronosyltransferase isoform 1A1 (UGT1A1) activity restored by AAV gene therapy in Gunn rats, a relevant animal model for CN I. Of these compounds, ezetimibe appeared most suitable because its glucuronidation rate in untreated control Gunn rats is low. Subsequently, ezetimibe glucuronidation was studied in both untreated and AAV-treated Gunn rats and the results suggest that it may serve as a useful serum marker for restored hepatic UGT1A1 activity.


Assuntos
Azetidinas/sangue , Síndrome de Crigler-Najjar/sangue , Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Glucuronosiltransferase/genética , Fígado/enzimologia , Animais , Azetidinas/administração & dosagem , Bilirrubina/sangue , Biomarcadores/sangue , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Modelos Animais de Doenças , Ezetimiba , Feminino , Vetores Genéticos/genética , Vetores Genéticos/metabolismo , Glucuronosiltransferase/biossíntese , Glucuronosiltransferase/metabolismo , Humanos , Hepatopatias/terapia , Masculino , Distribuição Aleatória , Ratos , Ratos Gunn
2.
FASEB J ; 26(3): 1052-63, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22094718

RESUMO

Crigler-Najjar type I (CNI) syndrome is a recessively inherited disorder characterized by severe unconjugated hyperbilirubinemia caused by uridine diphosphoglucuronosyltransferase 1A1 (UGT1A1) deficiency. The disease is lethal due to bilirubin-induced neurological damage unless phototherapy is applied from birth. However, treatment becomes less effective during growth, and liver transplantation is required. To investigate the pathophysiology of the disease and therapeutic approaches in mice, we generated a mouse model by introducing a premature stop codon in the UGT1a1 gene, which results in an inactive enzyme. Homozygous mutant mice developed severe jaundice soon after birth and died within 11 d, showing significant cerebellar alterations. To rescue neonatal lethality, newborns were injected with a single dose of adeno-associated viral vector 9 (AAV9) expressing the human UGT1A1. Gene therapy treatment completely rescued all AAV-treated mutant mice, accompanied by lower plasma bilirubin levels and normal brain histology and motor coordination. Our mouse model of CNI reproduces genetic and phenotypic features of the human disease. We have shown, for the first time, the full recovery of the lethal effects of neonatal hyperbilirubinemia. We believe that, besides gene-addition-based therapies, our mice could represent a very useful model to develop and test novel technologies based on gene correction by homologous recombination.


Assuntos
Síndrome de Crigler-Najjar/genética , Modelos Animais de Doenças , Terapia Genética/métodos , Glucuronosiltransferase/genética , Animais , Animais Recém-Nascidos , Bilirrubina/sangue , Northern Blotting , Western Blotting , Cerebelo/enzimologia , Cerebelo/metabolismo , Cerebelo/patologia , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/mortalidade , Dependovirus/classificação , Dependovirus/genética , Regulação Enzimológica da Expressão Gênica , Técnicas de Transferência de Genes , Vetores Genéticos/genética , Glucuronosiltransferase/deficiência , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Músculo Esquelético/enzimologia , Músculo Esquelético/metabolismo , Mutação , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Taxa de Sobrevida
3.
Gastroenterology ; 139(3): 999-1007, 1007.e1-2, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20546738

RESUMO

BACKGROUND & AIMS: Crigler-Najjar type 1 (CN-I) is an inherited liver disease caused by an absence of bilirubin-uridine 5'-diphosphate-glucuronosyltransferase (UGT1A1) activity. It results in life-threatening levels of unconjugated bilirubin, and therapeutic options are limited. We used adult Gunn rats (an animal model of the disease) to evaluate the efficiency of lentiviral-based gene therapy to express UGT1A1 in liver. METHODS: Gunn rats were given intraportal injections of VSVG-pseudotyped lentiviral vectors that encode UGT1A1 under the control of a liver-specific transthyretin promoter (mTTR.hUGT1A1); this vector does not contain target sequences for miR-142, a microRNA that is expressed specifically in hematopoietic cells. Rats were also injected with the vector mTTR.hUGT1A1.142T, which contains 4 copies of the miR-142 target sequences; its messenger RNA should be degraded in antigen-presenting cells. Bilirubinemia was monitored, and the presence of transduced hepatocytes was analyzed by quantitative polymerase chain reaction. Vector expression was tested in vitro in rat hematopoietic cells. RESULTS: In Gunn rats, bilirubin levels normalized 2 weeks after administration of mTTR.hUGT1A1. However, hyperbilirubinemia resumed 8 weeks after vector administration, concomitant with the induction of an immune response. In contrast, in rats injected with mTTR-UGT1A1.142T, bilirubin levels normalized for up to 6 months and transduced cells were not eliminated. CONCLUSIONS: Lentiviral vectors that express UGT1A1 reduce hyperbilirubinemia in immunocompetent Gunn rats for at least 6 months. The immune response against virally expressed UGT1A1 can be circumvented by inclusion of miR-142 target sequences, which reduce vector expression in antigen-presenting cells. This lentiviral-based gene therapy approach might be developed to treat patients with CN-I.


Assuntos
Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Vetores Genéticos , Glucuronosiltransferase/genética , Lentivirus/genética , Fígado/enzimologia , MicroRNAs/metabolismo , Animais , Anticorpos/sangue , Células Apresentadoras de Antígenos/imunologia , Bilirrubina/sangue , Biomarcadores/sangue , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Síndrome de Crigler-Najjar/imunologia , Modelos Animais de Doenças , Glucuronosiltransferase/biossíntese , Glucuronosiltransferase/imunologia , Células HeLa , Humanos , Masculino , Pré-Albumina/genética , Regiões Promotoras Genéticas , Estabilidade de RNA , RNA Mensageiro/metabolismo , Ratos , Ratos Gunn , Fatores de Tempo , Transdução Genética
4.
Cancer Chemother Pharmacol ; 61(4): 595-605, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17549477

RESUMO

We assessed the involvement of UDP-glucuronosyltransferase (UGT) activity in episodes of irinotecan hydrochloride (CPT-11)-induced delayed-onset diarrhea using a mutant rat strain with an inherited deficiency of UGT1A (Gunn rats). Gunn rats exhibited severe diarrhea after the intravenous administration of CPT-11 at a dose of 20 mg/kg, whereas Wistar rats did not. In the epithelium of the small intestine and cecum in Gunn rats, the shortening of villi, degeneration of crypts, and destruction of the nucleus were observed. The AUC, MRT, and t (1/2) of CPT-11, and the AUC of 7-ethyl-10-hydroxycamptothecin (SN-38) in plasma were, respectively, 1.6-fold, 1.5-fold, 1.7-fold, and 6.5-fold higher, and the cumulative biliary excretion rate of SN-38 was 2.3-fold higher, in Gunn rats than Wistar rats. SN-38 glucuronide excreted via bile in Wistar rats was not de-conjugated in the small intestinal lumen. The SN-38 AUC values in small intestinal tissues were also 5.0 to 5.8-fold higher in Gunn rats than Wistar rats. In conclusion, Gunn rats developed severe delayed-onset diarrhea after i.v. administration of CPT-11 at a much lower dose. Severe intestinal impairments would be induced in Gunn rats through exposure to SN-38 at high levels for a long period mainly via the intestinal lumen and partially via the bloodstream. These results clarified that the deficiency of UGT activity contributed greatly to the induction of the CPT-11-induced delayed-onset diarrhea and epithelial impairment in the intestine. In the clinic, great care is needed when using chemotherapy with CPT-11 in patients with poor UGT activity.


Assuntos
Antineoplásicos Fitogênicos/toxicidade , Camptotecina/análogos & derivados , Diarreia/induzido quimicamente , Diarreia/enzimologia , Glucuronosiltransferase/metabolismo , Algoritmos , Animais , Antineoplásicos Fitogênicos/farmacocinética , Área Sob a Curva , Bilirrubina/metabolismo , Camptotecina/metabolismo , Camptotecina/farmacocinética , Camptotecina/toxicidade , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Diarreia/patologia , Glucuronosiltransferase/deficiência , Glucuronosiltransferase/genética , Hiperbilirrubinemia/enzimologia , Hiperbilirrubinemia/genética , Intestinos/patologia , Irinotecano , Ratos , Ratos Gunn , Ratos Wistar
5.
Pharmacogenet Genomics ; 17(12): 1017-29, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18004206

RESUMO

OBJECTIVES: UGT1A1 coding region mutations, including UGT1A1*6 (G71R), UGT1A1*7 (Y486D), UGT1A1*27 (P229Q) and UGT1A1*62 (F83L), have been linked to Gilbert syndrome in Asian populations, whereas homozygosity for UGT1A1*7 is associated with the Crigler-Najjar syndrome type II. This work compared the effects of (a) the individual UGT1A1 mutations on the glucuronidation kinetics bilirubin, beta-estradiol, 4-methylumbelliferone (4MU) and 1-naphthol (1NP), and (b) the Y486 mutation, which occurs in the conserved carboxyl terminal domain of UGT1A enzymes, on 4MU, 1NP and naproxen glucuronidation by UGT1A3, UGT1A6 and UGT1A10. METHODS: Mutant UGT1A cDNAs were generated by site-directed mutagenesis and the encoded proteins were expressed in HEK293 cells. The glucuronidation kinetics of each substrate with each enzyme were characterized using specific high-performance liquid chromatography (HPLC) methods. RESULTS: Compared with wild-type UGT1A1, in-vitro clearances for bilirubin, beta-estradiol, 4MU and 1NP glucuronidation by UGT1A1*6 and UGT1A1*27 were reduced by 34-74%, most commonly as a result of a reduction in Vmax. However, the magnitude of the decrease in the in-vitro clearances varied from substrate to substrate with each mutant. The glucuronidation activities of UGT1A1*7 and UGT1A1*62 were reduced by >95%. Introduction of the Y486D mutation essentially abolished UGT1A6 and UGT1A10 activities, and resulted in 60-90% reductions in UGT1A3 in-vitro clearances. CONCLUSIONS: The glucuronidation of all UGT1A1 substrates is likely to be impaired in subjects carrying the UGT1A1*6 and UGT1A1*62 alleles, although the reduction in metabolic clearance might vary with the substrate. The Y486D mutation appears to greatly reduce most, but not all, UGT1A activities.


Assuntos
Bilirrubina/metabolismo , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Doença de Gilbert/enzimologia , Doença de Gilbert/genética , Glucuronosiltransferase/genética , Glucuronosiltransferase/metabolismo , Substituição de Aminoácidos , Linhagem Celular , Estradiol/metabolismo , Glucuronídeos/metabolismo , Humanos , Himecromona/análogos & derivados , Himecromona/metabolismo , Cinética , Mutagênese Sítio-Dirigida , Naftóis/metabolismo , Farmacogenética , Mutação Puntual , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Especificidade por Substrato
6.
Mol Ther ; 13(2): 374-81, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16337205

RESUMO

Treatment of congenital and acquired liver disease is one of the main issues in the field of gene therapy. Self-inactivating lentiviral vectors have several potential advantages over alternative systems. We have constructed a self-inactivating lentiviral vector (LV-ALBUGT) that expresses the human bilirubin UDP-glucuronosyltransferase (UGT1A1) from a liver-specific promoter. UGT1A1 is involved in the clearance of heme metabolites in the liver. This enzyme is deficient in Crigler-Najjar disease, a recessive inherited disorder in humans characterized by chronic severe jaundice, i.e., high plasma bilirubin levels. Gunn rats suffer from the same defect and are used as an animal model of this disease. We have treated juvenile Gunn rats by single intravenous injection with the LV-ALBUGT vector. Over 1 year after treatment with the highest dose (5 x 10(8) transducing units), we observed a stable reduction of bilirubin levels to near normal levels and normal secretion of bilirubin conjugates in the bile, in contrast to untreated animals. In situ hybridization showed expression of the therapeutic gene in more than 30% of liver parenchymal cells. Thus, we demonstrate stable and complete clinical remission of a congenital metabolic liver disease in an animal model, after systemic administration of a therapeutic lentiviral vector.


Assuntos
Síndrome de Crigler-Najjar/terapia , Terapia Genética , Vetores Genéticos/administração & dosagem , Glucuronosiltransferase/administração & dosagem , Glucuronosiltransferase/deficiência , Lentivirus/genética , Fígado/virologia , Animais , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/virologia , Linhagem Celular , Linhagem Celular Tumoral , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Modelos Animais de Doenças , Feminino , Terapia Genética/métodos , Vetores Genéticos/uso terapêutico , Glucuronosiltransferase/genética , Glucuronosiltransferase/uso terapêutico , Humanos , Injeções Intravenosas , Fígado/patologia , Masculino , Camundongos , Ratos , Ratos Gunn
7.
Ann Clin Biochem ; 40(Pt 5): 528-33, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14503990

RESUMO

BACKGROUND: Patients with Crigler-Najjar syndrome, type I (CNS-I) have an inherited absence of hepatocellular bilirubin uridine diphosphate-glucuronosyltransferase activity, which results in severe unconjugated hyperbilirubinaemia, often causing kernicterus and death in infancy or childhood. METHODS: Our patient is a 19-year-old Japanese man with CNS-I diagnosed by the complete absence of the hepatocellular enzyme in a liver biopsy and genotyping. The efficacies of the removal of protein-bound (PBB) and unbound (UB) unconjugated bilirubin by phototherapy, plasma perfusion and liver transplantation were compared in the patient. RESULTS: At the age of 5 years, phototherapy treatment reduced the patient's PBB by 21% and UB by 34%, and 98% of the bilirubin produced daily was removed. At the age of 16 years, plasma perfusion combined with nightly phototherapy completely removed the daily production of bilirubin; however, by 24 h post-treatment, the PBB and UB were again increased. Apparently, these treatments were effective in reducing PBB and UB, but the effect was only temporary. Following liver transplantation, PBB and UB decreased to normal concentrations. CONCLUSIONS: Liver transplantation as a potential cure should be performed at a younger age, particularly in confirmed CNS-I cases for which reliable effects of phototherapy cannot be guaranteed.


Assuntos
Resinas de Troca Aniônica/química , Bilirrubina/isolamento & purificação , Bilirrubina/metabolismo , Síndrome de Crigler-Najjar/sangue , Proteínas/metabolismo , Adolescente , Terapia Combinada , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/cirurgia , Síndrome de Crigler-Najjar/terapia , Humanos , Fígado/metabolismo , Transplante de Fígado , Masculino , Perfusão , Fototerapia
8.
Pediatrics ; 111(6 Pt 1): 1262-7, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12777539

RESUMO

OBJECTIVE: Transplantation of isolated hepatocytes in animal models has been shown to correct inborn errors of metabolism. Based on these studies and our experience with hepatocyte transplantation in a child with Crigler-Najjar syndrome, isolated hepatocyte transplantation was performed to attempt metabolic reconstitution in a male infant with severe ornithine transcarbamylase (OTC) deficiency. METHODS: An infant with an antenatal diagnosis of OTC deficiency was managed intensively to prevent hyperammonemia. Isolated hepatocytes were obtained by collagenase perfusion of donated livers not used for transplantation. Hepatocytes were infused in batches over the first 4 weeks of life via an umbilical venous catheter positioned in the portal vein. Immunosuppression consisted of tacrolimus and corticosteroids. RESULTS: Over 4 billion viable hepatocytes were transplanted during the first 3.5 weeks of life. A period of metabolic stability was achieved between days 20 and 31 during which normal protein intake was tolerated while phenylbutyrate was weaned. During this time, plasma ammonia and glutamine remained within normal limits. Hyperammonemia reappeared abruptly on day 31 of life. Protein tolerance diminished to baseline; metabolic stability was subsequently reattained only following successful liver transplantation at 6 months of age. CONCLUSIONS: Isolated hepatocyte transplantation appeared to result in temporary relief of hyperammonemia and protein intolerance attributable to OTC deficiency. The metabolic stability achieved was lost after 11 days presumably because of rejection of the transplanted cells because of insufficient immunosuppression. Future attempts at isolated hepatocyte transplantation for inborn errors of metabolism in humans should include adequate immunosuppression and a liver biopsy as a means of proving hepatocyte engraftment and function.


Assuntos
Síndrome de Crigler-Najjar/terapia , Hepatócitos/transplante , Doença da Deficiência de Ornitina Carbomoiltransferase/terapia , Ureia/metabolismo , Adulto , Síndrome de Crigler-Najjar/diagnóstico , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Feminino , Triagem de Portadores Genéticos , Humanos , Hiperamonemia/enzimologia , Hiperamonemia/terapia , Lactente , Transplante de Fígado , Masculino , Doença da Deficiência de Ornitina Carbomoiltransferase/diagnóstico , Doença da Deficiência de Ornitina Carbomoiltransferase/genética , Diagnóstico Pré-Natal
9.
Am J Med Genet ; 79(1): 12-5, 1998 Aug 27.
Artigo em Inglês | MEDLINE | ID: mdl-9738861

RESUMO

Crigler-Najjar (CN) syndrome is a congenital familial nonhemolytic jaundice associated with high level of unconjugated bilirubin due to deficient uridine diphosphate glucuronosyltransferase (UDPG-T) activity in the liver. The aim of this report is to emphasize the need for increased awareness of this potentially fatal condition unless diagnosed early and managed appropriately. Between 1986-1994, 12 patients (8 males and 4 females) were diagnosed at our hospital with CN syndrome. Jaundice was detected in the first few days of life in all but one, in whom detection was delayed for two weeks and resulted in kernicterus. Exchange transfusions were necessary in six cases. Consanguinity was present in 11 patients, eight of whom were the offspring of first cousins. None of the patients responded to phenobarbital therapy alone, which reflects the severity of their disease. Six patients required only phototherapy while the remaining six patients required a combination of phenobarbital and phototherapy. Percutaneous liver biopsy, performed in 10 patients, showed minimal and focal cholestasis in eight, while the remaining two had a normal histological picture. Almost complete absence of the activity of UDPGT in the liver was reported in seven cases. Kernicterus developed in five cases. It is concluded that CN syndrome remains a potentially fatal condition unless diagnosed early and managed appropriately. The recent adoption of liver segment transplantation, whether orthotopic or living-related, has saved affected patients the daily long hours of phototherapy. One of our patients successfully underwent living-related segmental liver transplantation.


Assuntos
Síndrome de Crigler-Najjar , Pré-Escolar , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/patologia , Feminino , Glucuronosiltransferase/metabolismo , Humanos , Lactente , Fígado/enzimologia , Fígado/patologia , Masculino , Arábia Saudita
10.
Hum Gene Ther ; 9(4): 497-505, 1998 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-9525311

RESUMO

Crigler-Najjar syndrome type 1 (CN type 1) is an autosomal recessive disorder characterized by nonhemolytic jaundice resulting from mutations to the gene encoding bilirubin-UDP-glucuronosyltransferase (UDPGT). The Gunn rat is an accurate animal model of this disease because the bilirubin-UDPGT gene in this strain carries a premature stop codon. The primary objective of this study was to complement this deficiency in vivo using liver-directed gene therapy. The efficiency of adenovirus type 5 (Ad5)-mediated gene transfer to the neonatal rat liver was first assessed by intravenous (i.v.) injection of an Ad5 vector carrying a nuclear-localized LacZ gene. An Ad5 vector expressing the cDNA encoding human bilirubin-UDPGT (Ad5/CMV/hUG-Br1) was then generated and injected i.v. into neonatal Gunn rats. Plasma samples were collected and bilirubin levels were determined at regular intervals. Although the mean level of bilirubin in homozygous Gunn rats 1-2 days after birth was already 14.5-fold higher than that of heterozygous siblings, treatment with Ad5/CMV/hUG-Br1 reduced plasma bilirubin to normal levels within 1 week. Plasma bilirubin in the treated homozygous rats remained normal for 4 weeks before gradually climbing to intermediate levels that were approximately half that of untreated homozygotes by 12 weeks. Administration of Ad5-mediated gene therapy to neonatal Gunn rats effectively complemented the deficiency in bilirubin-UDPGT, resulting in substantial reductions in plasma bilirubin over a 3-month period. The efficacy of Ad5-mediated gene therapy in neonates suggests that this approach might be effective against other hepatic disorders, including autosomal recessive deficiencies in lipid metabolism and vascular homeostasis.


Assuntos
Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Glucuronosiltransferase/genética , Adenovírus Humanos/genética , Alanina Transaminase/sangue , Animais , Animais Recém-Nascidos , Bilirrubina/sangue , Síndrome de Crigler-Najjar/enzimologia , Modelos Animais de Doenças , Técnicas de Transferência de Genes , Vetores Genéticos/administração & dosagem , Vetores Genéticos/genética , Homozigoto , Humanos , Icterícia , Óperon Lac/genética , Fígado/metabolismo , Sinais de Localização Nuclear , Ratos , Ratos Gunn
11.
N Engl J Med ; 333(18): 1171-5, 1995 Nov 02.
Artigo em Inglês | MEDLINE | ID: mdl-7565971

RESUMO

BACKGROUND: People with Gilbert's syndrome have mild, chronic unconjugated hyperbilirubinemia in the absence of liver disease or overt hemolysis. Hepatic glucuronidating activity, essential for efficient biliary excretion of bilirubin, is reduced to about 30 percent of normal. METHODS: We sequenced the coding and promoter regions of the gene for bilirubin UDP-glucuronosyltransferase 1 (bilirubin/uridine diphosphoglucuronate-glucuronosyltransferase 1)--the only enzyme that contributes substantially to bilirubin glucuronidation--in 10 unrelated patients with Gilbert's syndrome, 16 members of a kindred with a history of Crigler-Najjar syndrome type II, and 55 normal subjects. RESULTS: The coding region of the gene for the enzyme was normal in the 10 patients with Gilbert's syndrome. These patients were homozygous for two extra bases (TA) in the TATAA element of the 5' promoter region of the gene (A(TA)7TAA rather than the normal A(TA)6TAA). The presence of the longer TATAA element resulted in the reduced expression of a reporter gene, encoding firefly luciferase, in a human hepatoma cell line. The frequency of the abnormal allele was 40 percent among the normal subjects. The 3 men in the control group who were homozygous for the longer TATAA element had significantly higher serum bilirubin levels than the other 52 normal subjects (P = 0.009). Among the kindred with a history of Crigler-Najjar syndrome type II, only the six heterozygous carriers who had a longer TATAA element on the structurally normal allele had mild hyperbilirubinemia, characteristic of Gilbert's syndrome. CONCLUSIONS: Reduced expression of bilirubin UDP-glucuronosyltransferase 1 due to an abnormality in the promoter region of the gene for this enzyme appears to be necessary for Gilbert's syndrome but not sufficient for the complete manifestation of the syndrome.


Assuntos
Regulação Enzimológica da Expressão Gênica/genética , Doença de Gilbert/genética , Glucuronosiltransferase/genética , Mutação , TATA Box , Adolescente , Adulto , Sequência de Bases , Estudos de Casos e Controles , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Feminino , Doença de Gilbert/enzimologia , Homozigoto , Humanos , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular
12.
Gene Ther ; 2(3): 203-8, 1995 May.
Artigo em Inglês | MEDLINE | ID: mdl-7614251

RESUMO

Crigler-Najjar syndrome type I (CN-I) is a congenital hepatic metabolic deficiency in bilirubin UDP-glucuronosyltransferase activity which leads to profound jaundice and death from kernicterus. UGT1, the gene locus coding for multiple glucuronosyltransferase isoforms, has been well characterized and the cDNA for the most active form, HUG Br1, has been cloned. Recent advances in liver directed gene transfer suggest that this disease could be treated through gene therapy. As an initial step to correct the genetic defect in Crigler-Najjar type I, recombinant retroviruses were used to transduce an HUG Br1 gene into hepatocytes of a rat model of CN-I and CN-I fibroblasts. The retroviral vector gagCMVBA HUG Br1 was constructed and helper-free amphotrophic virus was isolated and used to transfer bilirubin UDP-glucuronosyltransferase activity to genetically deficient cells. The efficiency of transduction as measured by Southern blot analysis of integrated proviral sequences in DNA of recipient cells ranged from 5 to 100%. HUG Br1 gene expression was documented by blot hybridization analysis of total cellular RNA, immunotransblot analysis using a rabbit polyclonal antipeptide HUG Br1 antibody, and lysate enzymatic assay of bilirubin UDP-glucuronosyltransferase activity. HUG Br1 gene transfer was definitively demonstrated by four independent modalities following HUG Br1 retroviral transduction.


Assuntos
Síndrome de Crigler-Najjar/genética , Fibroblastos/enzimologia , Técnicas de Transferência de Genes , Glucuronosiltransferase/genética , Fígado/enzimologia , Sequência de Aminoácidos , Animais , Sequência de Bases , Bilirrubina/metabolismo , Síndrome de Crigler-Najjar/enzimologia , Expressão Gênica , Vetores Genéticos/genética , Glucuronosiltransferase/biossíntese , Glucuronosiltransferase/metabolismo , Humanos , Fígado/citologia , Dados de Sequência Molecular , Fragmentos de Peptídeos/síntese química , Fragmentos de Peptídeos/imunologia , Provírus/genética , Ratos , Ratos Gunn , Retroviridae/genética
13.
Toxicol Appl Pharmacol ; 127(2): 306-13, 1994 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8048075

RESUMO

UDP-glucuronosyltransferases (UGTs) play a major role in the elimination of nucleophilic metabolites of xenobiotics, such the phenols and quinols of polycyclic aromatic hydrocarbons, including benzo[a]pyrene (BP). In this way, UGTs may prevent the further oxidation of such metabolites to toxic reactive intermediates, which may react with lipids, DNA, RNA, and protein, thereby initiating such toxicities as cellular necrosis, birth defects, and cancer. We have shown previously in vivo and in hepatic microsomes that rats with a hereditary deficiency in bilirubin UGT (Gunn and RHA strains) have decreased glucuronidation of BP metabolites and enhanced BP covalent binding to hepatic DNA and microsomal protein, and enhanced BP embryotoxicity. We further hypothesized that a similar deficiency in BP glucuronidation, with increased BP bioactivation and covalent binding, might be observed in peripheral blood lymphocytes from UGT-deficient rats, which, if true, would suggest the utility of an analogous human lymphocyte model for evaluating the toxicological relevance of human UGT deficiencies. Such an in vitro approach is essential for human studies of environmental chemicals and drugs with a high toxicologic potential. In the current study, [7,10(-14)C]BP was preincubated with NADPH and hepatic microsomes from Wistar rats induced with beta-naphthoflavone. The supernatant from this preincubation, which contained BP reactive intermediates and hydroxylated BP metabolites, was further incubated with uridine diphosphate glucuronic acid and peripheral lymphocytes from heterozygous (j/+) and homozygous (j/j) RHA rats, which are genetically deficient in bilirubin UGT, and from congenic, homozygous (+/+) UGT-normal controls. In vivo, bilirubin glucuronidation was reduced in UGT deficiency, with progressively higher plasma concentrations of unconjugated bilirubin in j/+ and j/j UGT-deficient rats compared to +/+ UGT-normal controls (p < 0.05). In in vitro studies, glucuronide conjugates of BP were measured by high-performance liquid chromatography with a radioisotope detector, and the covalent binding of BP to microsomal protein was measured by liquid scintillation spectrometry. BP glucuronidation and covalent binding, respectively, were decreased and increased to a progressively greater degree in both hepatic microsomes and lymphocytes from j/+ and j/j UGT-deficient rats compared to +/+ UGT-normal controls (p < 0.05). Reduced BP glucuronidation in lymphocytes from UGT-deficient RHA rats correlated with elevated BP covalent binding (R2 = 0.85, p < 0.005). Both BP glucuronidation and BP covalent binding in lymphocytes significantly correlated with those reactions using hepatic microsomes from the same animals. These results in UGT-deficient lymphocytes also accurately reflected the in vivo biotransformation and covalent binding of BP in UGT-deficient rats.(ABSTRACT TRUNCATED AT 400 WORDS)


Assuntos
Benzo(a)pireno/farmacocinética , Glucosiltransferases/deficiência , Linfócitos/metabolismo , Microssomos Hepáticos/metabolismo , Animais , Benzo(a)pireno/metabolismo , Benzo(a)pireno/toxicidade , Biotransformação , Proteínas Sanguíneas/metabolismo , Síndrome de Crigler-Najjar/enzimologia , Feminino , Glucosiltransferases/genética , Glucosiltransferases/metabolismo , Glucuronatos/metabolismo , Ligação Proteica , Proteínas/metabolismo , Ratos , Ratos Endogâmicos
14.
FASEB J ; 6(10): 2859-63, 1992 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-1634050

RESUMO

Crigler-Najjar syndrome, type I (CN-I) is a potentially lethal disorder characterized by severe unconjugated hyperbilirubinemia resulting from a recessively inherited deficiency of hepatic UDP-glucuronosyl-transferase (UGT) activity toward bilirubin (B-UGT). Two forms of B-UGT exist in human liver. mRNAs for these two forms and that for another isoform with activity toward simple phenols (P-UGT) have unique 5' regions, but their 3' regions are identical. The three mRNA species are derived from a single locus; the unique 5' regions are encoded by single unique exons and the identical 3' regions consist of four consecutive exons that are shared by all three isoforms. In this paper, we determined genetic lesions in two CN-I patients with deficiency of hepatic B-UGT and P-UGT activities. In one patient, there was a C----T substitution in exon 4 (common region) predicting the substitution of a serine residue with a phenylalanine residue; this mutation was present in the identical region of B-UGT and P-UGT mRNAs. In the other patient, a C----T substitution in exon 2 (common region) of the B-UGT/P-UGT locus resulted in a premature stop codon. This exon (132 nt) was absent in heptic B-UGT and P-UGT mRNAs of this patient due to exon skipping during pre-mRNA processing. Sequence abnormality of three distinct mRNA species explains the abnormality of multiple UGT isoforms in these patients. Presence of identical abnormalities in the common regions of the three mRNAs is consistent with the finding that the common 3' regions of the two B-UGT mRNAs and the P-UGT mRNA are encoded by four shared exons.


Assuntos
Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Glucuronosiltransferase/deficiência , Glucuronosiltransferase/genética , Isoenzimas/genética , Androsterona/metabolismo , Sequência de Bases , Bilirrubina/metabolismo , Northern Blotting , Mapeamento Cromossômico , Eletroforese em Gel de Ágar , Estradiol/metabolismo , Humanos , Himecromona/metabolismo , Fígado/metabolismo , Dados de Sequência Molecular , Nitrofenóis/metabolismo , Reação em Cadeia da Polimerase , RNA Mensageiro/análise
15.
J Inherit Metab Dis ; 14(4): 563-79, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1749222

RESUMO

Liver biopsy samples were obtained from eight Crigler-Najjar patients. Bilirubin UDPGT activity, assayed by a microassay with HPLC analysis, was not detectable in type I livers, and low levels (9-26% of controls) of monoglucuronide conjugates only were observed in type II livers. 1-Naphthol UDPGT activity was normal in most patients, where membrane integrity was maintained by correct sample procurement and preparation. Our data on type II livers suggest that a defect in UDPGA transport is an unlikely cause of the hyperbilirubinaemia, but reduced affinity for UDPGA was observed in one sample. Analysis of four patient liver samples by immunoblot analysis revealed the heterogeneous nature of this inherited disease within the patient population, and one sample where 1-naphthol UDPGT activity was considerably reduced appeared to correlate with the non-detection of a phenol UDPGT protein. Progress towards a molecular genetic diagnosis of Crigler-Najjar syndromes is discussed.


Assuntos
Síndrome de Crigler-Najjar/genética , Glucuronosiltransferase/deficiência , Idoso , Síndrome de Crigler-Najjar/enzimologia , Feminino , Glucuronosiltransferase/genética , Glucuronosiltransferase/metabolismo , Humanos , Lactente , Recém-Nascido , Fígado/enzimologia , Fígado/patologia , Masculino
16.
J Clin Invest ; 85(4): 1199-205, 1990 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-2108190

RESUMO

The functional heterogeneity of uridine diphosphate-glucuronosyltransferase (UDPGT) and its deficiency in human liver were investigated. The monoclonal antibody (MAb) WP1, which inhibits bilirubin and phenol-glucuronidating activity, was used to immunopurify UDPGTs from human liver. Purified UDPGTs were injected into mice to obtain new MAbs. Immunoblotting of microsomes with MAb HEB7 revealed at least three polypeptides in liver (56, 54, and 53 kD) and one in kidney (54 kD). In liver microsomes from four patients (A, B, C, and D) with Crigler-Najjar syndrome type I (CN type I), UDPGT activity towards bilirubin was undetectable (A, B, C, and D) and activity towards phenolic compounds and 5-hydroxytryptamine either reduced (A and B) or normal (C and D). UDPGT activity toward steroids was normal. Immunoblot studies revealed that the monoclonal antibody WP1 recognized two polypeptides (56 and 54 kD) in liver microsomes from patient A and none in patient B. With HEB7 no immunoreactive polypeptides were seen in these two patients. Patient C showed a normal banding pattern and in patient D only the 53-kD band showed decreased intensity. These findings suggest considerable heterogeneity with regard to the expression of UDPGT isoenzymes among CN type I patients.


Assuntos
Síndrome de Crigler-Najjar/enzimologia , Glucuronosiltransferase/análise , Hiperbilirrubinemia Hereditária/enzimologia , Animais , Anticorpos Monoclonais , Glucuronosiltransferase/imunologia , Glucuronosiltransferase/isolamento & purificação , Humanos , Immunoblotting , Imunoquímica , Isoenzimas/análise , Camundongos , Camundongos Endogâmicos BALB C , Microssomos Hepáticos/enzimologia , Coelhos
17.
Gastroenterol Jpn ; 17(3): 235-40, 1982.
Artigo em Inglês | MEDLINE | ID: mdl-6214447

RESUMO

Bilirubin UDP-glucuronyl transferase (BGT), bilirubin UDP-glucosyl transferase (BGLT) and bilirubin UDP-xylosyl transferase (BXT) activities were measured in wedge-biopsied liver specimens obtained from patients with various liver diseases, and compared with those in controls with normal liver histology. BGT was measured alone using needle biopsy liver specimens from the patients with Gilbert's syndrome (15 patients). Rotor's syndrome (one) and posthepatitic hyperbilirubinemia (3). BGT was decreased to about 30% of controls in Gilbert's syndrome, but showed no change in posthepatitic hyperbilirubinemia and Rotor's syndrome. About 90% decrease in BGT, and BGLT and BXT were observed in Crigler-Najjar syndrome type II (3 patients). In patients with cholelithiasis and chronic hepatitis, statistically significant changes of these three enzymes were not observed, except the statistically significant increase in BGT activity in chronic hepatitis. Slight increases in BGT and BXT activities were observed in anicteric cases with cholelithiasis. The ratio of BGT, BGLT and BXT activities in controls was 1:0.50:0.98 (expressed as "per mg protein"). Slight differences existed between the ratios of BGT, BGLT and BXT in various liver diseases, and this may suggest the separate identities of BGLT and BXT from BGT. Determination of bilirubin-conjugation is essential in the diagnosis of Gilbert's syndrome and Crigler-Najjar syndrome type II, but shows no specific change in the other chronic liver diseases.


Assuntos
Glucosiltransferases/metabolismo , Glucuronosiltransferase/metabolismo , Hepatopatias/enzimologia , Fígado/enzimologia , Pentosiltransferases/metabolismo , Síndrome de Crigler-Najjar/enzimologia , Feminino , Doença de Gilbert/enzimologia , Humanos , Lactente , Masculino , Úlcera Gástrica/enzimologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA